Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genome-Wide Association Study | 16 | 2022 | 1763 | 1.620 |
Why?
|
| Phenotype | 8 | 2018 | 2579 | 0.850 |
Why?
|
| Models, Genetic | 4 | 2017 | 983 | 0.810 |
Why?
|
| Alcoholism | 2 | 2022 | 191 | 0.760 |
Why?
|
| Genetic Predisposition to Disease | 11 | 2022 | 2473 | 0.700 |
Why?
|
| Asthma | 10 | 2018 | 1051 | 0.610 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2018 | 2494 | 0.520 |
Why?
|
| Biostatistics | 1 | 2016 | 21 | 0.490 |
Why?
|
| Genes | 1 | 2017 | 308 | 0.480 |
Why?
|
| Genotyping Techniques | 1 | 2013 | 71 | 0.390 |
Why?
|
| Genotype | 6 | 2019 | 1882 | 0.370 |
Why?
|
| Substance-Related Disorders | 1 | 2016 | 451 | 0.350 |
Why?
|
| Genetic Loci | 6 | 2017 | 260 | 0.300 |
Why?
|
| Allergens | 1 | 2008 | 191 | 0.270 |
Why?
|
| Multifactorial Inheritance | 2 | 2022 | 201 | 0.260 |
Why?
|
| Hypersensitivity | 1 | 2008 | 166 | 0.260 |
Why?
|
| Gene-Environment Interaction | 2 | 2016 | 120 | 0.220 |
Why?
|
| Databases, Genetic | 2 | 2016 | 282 | 0.220 |
Why?
|
| Linkage Disequilibrium | 3 | 2022 | 481 | 0.210 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 1010 | 0.200 |
Why?
|
| Nitric Oxide Synthase Type II | 3 | 2008 | 89 | 0.190 |
Why?
|
| Computer Simulation | 2 | 2016 | 1158 | 0.180 |
Why?
|
| Longitudinal Studies | 2 | 2022 | 1175 | 0.170 |
Why?
|
| Humans | 25 | 2022 | 96127 | 0.160 |
Why?
|
| Receptors, GABA-A | 1 | 2019 | 35 | 0.160 |
Why?
|
| Michigan | 4 | 2019 | 57 | 0.160 |
Why?
|
| Eosinophil-Derived Neurotoxin | 1 | 2018 | 2 | 0.150 |
Why?
|
| Adolescent Behavior | 1 | 2019 | 115 | 0.140 |
Why?
|
| Eosinophils | 1 | 2018 | 199 | 0.140 |
Why?
|
| Genetic Pleiotropy | 1 | 2017 | 29 | 0.130 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 294 | 0.130 |
Why?
|
| Risk Factors | 4 | 2022 | 5960 | 0.120 |
Why?
|
| Monte Carlo Method | 1 | 2016 | 191 | 0.120 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2017 | 305 | 0.120 |
Why?
|
| Principal Component Analysis | 1 | 2016 | 168 | 0.110 |
Why?
|
| Dermatitis, Atopic | 1 | 2015 | 66 | 0.110 |
Why?
|
| Genetic Markers | 1 | 2015 | 479 | 0.110 |
Why?
|
| Ventricular Remodeling | 2 | 2005 | 115 | 0.110 |
Why?
|
| Albuterol | 1 | 2014 | 35 | 0.110 |
Why?
|
| Forced Expiratory Volume | 1 | 2014 | 136 | 0.110 |
Why?
|
| Rhinitis, Allergic | 1 | 2014 | 52 | 0.100 |
Why?
|
| Sarcoidosis | 1 | 2014 | 74 | 0.100 |
Why?
|
| Transmembrane Activator and CAML Interactor Protein | 1 | 2013 | 8 | 0.100 |
Why?
|
| beta-Defensins | 1 | 2013 | 12 | 0.100 |
Why?
|
| Chemokine CXCL12 | 1 | 2013 | 38 | 0.100 |
Why?
|
| Chemokines, CC | 1 | 2013 | 37 | 0.100 |
Why?
|
| Child | 8 | 2019 | 7626 | 0.100 |
Why?
|
| Kv Channel-Interacting Proteins | 1 | 2013 | 9 | 0.100 |
Why?
|
| Body Mass Index | 2 | 2014 | 815 | 0.100 |
Why?
|
| Kallikreins | 1 | 2012 | 46 | 0.100 |
Why?
|
| B-Cell Activating Factor | 1 | 2012 | 8 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2012 | 61 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2016 | 594 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 1981 | 0.090 |
Why?
|
| Family | 1 | 2014 | 332 | 0.090 |
Why?
|
| Heart | 2 | 2005 | 592 | 0.090 |
Why?
|
| Regression Analysis | 1 | 2013 | 599 | 0.090 |
Why?
|
| Male | 17 | 2019 | 45870 | 0.090 |
Why?
|
| Adolescent | 8 | 2019 | 9896 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 312 | 0.090 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 321 | 0.090 |
Why?
|
| Respiration | 1 | 2013 | 281 | 0.090 |
Why?
|
| Myocardial Infarction | 2 | 2005 | 429 | 0.090 |
Why?
|
| Models, Molecular | 1 | 2016 | 1375 | 0.090 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2008 | 77 | 0.090 |
Why?
|
| Beclomethasone | 1 | 2010 | 16 | 0.090 |
Why?
|
| Surveys and Questionnaires | 2 | 2016 | 2860 | 0.080 |
Why?
|
| Young Adult | 7 | 2019 | 7025 | 0.080 |
Why?
|
| Pharmacogenetics | 1 | 2014 | 456 | 0.080 |
Why?
|
| Prostate-Specific Antigen | 1 | 2012 | 346 | 0.080 |
Why?
|
| Adult | 10 | 2019 | 28718 | 0.080 |
Why?
|
| Adenocarcinoma | 2 | 2007 | 1215 | 0.080 |
Why?
|
| Genetics, Population | 1 | 2013 | 437 | 0.080 |
Why?
|
| Restraint, Physical | 1 | 2009 | 32 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2018 | 3107 | 0.080 |
Why?
|
| Neck Injuries | 1 | 2009 | 15 | 0.080 |
Why?
|
| Spinal Injuries | 1 | 2009 | 29 | 0.080 |
Why?
|
| Wounds, Penetrating | 1 | 2009 | 56 | 0.080 |
Why?
|
| Hypertension, Renovascular | 1 | 2008 | 12 | 0.070 |
Why?
|
| Suburban Population | 1 | 2008 | 6 | 0.070 |
Why?
|
| Myocardium | 3 | 2008 | 596 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2014 | 3974 | 0.070 |
Why?
|
| Genomics | 1 | 2014 | 855 | 0.070 |
Why?
|
| Immunoglobulin E | 1 | 2008 | 152 | 0.070 |
Why?
|
| Spinal Cord Injuries | 1 | 2009 | 115 | 0.070 |
Why?
|
| Smoking | 2 | 2014 | 653 | 0.070 |
Why?
|
| 3-Hydroxysteroid Dehydrogenases | 1 | 2007 | 22 | 0.070 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2007 | 9 | 0.070 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 1 | 2007 | 12 | 0.070 |
Why?
|
| DNA Adducts | 1 | 2007 | 22 | 0.070 |
Why?
|
| Female | 12 | 2019 | 50063 | 0.070 |
Why?
|
| Disease Progression | 3 | 2018 | 1568 | 0.070 |
Why?
|
| Urban Population | 1 | 2008 | 240 | 0.070 |
Why?
|
| United States | 6 | 2018 | 7767 | 0.060 |
Why?
|
| Lung | 1 | 2013 | 1382 | 0.060 |
Why?
|
| Oxidative Stress | 2 | 2008 | 484 | 0.060 |
Why?
|
| Prostatic Neoplasms | 2 | 2007 | 1798 | 0.060 |
Why?
|
| Obesity | 1 | 2013 | 1034 | 0.060 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 639 | 0.060 |
Why?
|
| Isoproterenol | 1 | 2005 | 62 | 0.060 |
Why?
|
| Environmental Exposure | 1 | 2008 | 357 | 0.060 |
Why?
|
| Alleles | 2 | 2019 | 1157 | 0.060 |
Why?
|
| Receptor, Bradykinin B1 | 1 | 2005 | 2 | 0.060 |
Why?
|
| Infant | 2 | 2009 | 3363 | 0.060 |
Why?
|
| Cardiotonic Agents | 1 | 2005 | 95 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2007 | 829 | 0.050 |
Why?
|
| Risk | 2 | 2017 | 668 | 0.050 |
Why?
|
| Middle Aged | 8 | 2018 | 28363 | 0.050 |
Why?
|
| Heart Ventricles | 2 | 2005 | 810 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2008 | 2614 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2005 | 343 | 0.050 |
Why?
|
| Administration, Inhalation | 2 | 2014 | 203 | 0.050 |
Why?
|
| Blood Pressure | 4 | 2008 | 929 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2007 | 1268 | 0.040 |
Why?
|
| Pregnancy | 1 | 2008 | 3240 | 0.040 |
Why?
|
| Logistic Models | 2 | 2014 | 1268 | 0.040 |
Why?
|
| Prognosis | 3 | 2016 | 4033 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2015 | 1958 | 0.040 |
Why?
|
| Internal-External Control | 1 | 2019 | 45 | 0.040 |
Why?
|
| Hypertension | 1 | 2005 | 777 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 4 | 2008 | 3490 | 0.040 |
Why?
|
| Peer Group | 1 | 2019 | 94 | 0.040 |
Why?
|
| Metered Dose Inhalers | 1 | 2018 | 33 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2018 | 228 | 0.040 |
Why?
|
| Pharmacogenomic Variants | 1 | 2018 | 44 | 0.040 |
Why?
|
| Histone Code | 1 | 2017 | 19 | 0.030 |
Why?
|
| Mice, Knockout | 3 | 2008 | 2163 | 0.030 |
Why?
|
| Aged | 5 | 2014 | 20964 | 0.030 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2017 | 179 | 0.030 |
Why?
|
| Mice | 5 | 2013 | 12562 | 0.030 |
Why?
|
| Leukocytes | 1 | 2017 | 218 | 0.030 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2016 | 75 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2018 | 9173 | 0.030 |
Why?
|
| Organ Size | 2 | 2008 | 379 | 0.030 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2016 | 93 | 0.030 |
Why?
|
| Heart Failure | 1 | 2005 | 1422 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 992 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2014 | 50 | 0.030 |
Why?
|
| Bronchodilator Agents | 1 | 2014 | 70 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 554 | 0.020 |
Why?
|
| Immunity, Mucosal | 1 | 2013 | 72 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2013 | 156 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 84 | 0.020 |
Why?
|
| Insurance Claim Review | 1 | 2012 | 47 | 0.020 |
Why?
|
| Environment | 1 | 2014 | 231 | 0.020 |
Why?
|
| Pedigree | 1 | 2014 | 982 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2014 | 300 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2015 | 464 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 1807 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2015 | 684 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 554 | 0.020 |
Why?
|
| Animals | 5 | 2013 | 28945 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2014 | 7232 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 488 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2013 | 703 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 547 | 0.020 |
Why?
|
| Braces | 1 | 2009 | 14 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 901 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 2009 | 72 | 0.020 |
Why?
|
| Base Sequence | 1 | 2013 | 2344 | 0.020 |
Why?
|
| Sex Factors | 1 | 2012 | 1133 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 1316 | 0.020 |
Why?
|
| Nitrites | 1 | 2008 | 34 | 0.020 |
Why?
|
| Renin | 1 | 2008 | 67 | 0.020 |
Why?
|
| Nitrates | 1 | 2008 | 36 | 0.020 |
Why?
|
| Trauma Centers | 1 | 2009 | 174 | 0.020 |
Why?
|
| Surgical Instruments | 1 | 2008 | 63 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2015 | 1276 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2012 | 594 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2016 | 4671 | 0.020 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2007 | 7 | 0.020 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2007 | 10 | 0.020 |
Why?
|
| Epoxide Hydrolases | 1 | 2007 | 7 | 0.020 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2007 | 18 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2008 | 358 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2007 | 42 | 0.020 |
Why?
|
| Fibrosis | 1 | 2008 | 246 | 0.020 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2007 | 44 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2007 | 78 | 0.020 |
Why?
|
| Glutathione Transferase | 1 | 2007 | 116 | 0.020 |
Why?
|
| Hospitalization | 1 | 2012 | 943 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2007 | 218 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2012 | 2092 | 0.020 |
Why?
|
| Desoxycorticosterone | 1 | 2005 | 18 | 0.020 |
Why?
|
| Comorbidity | 1 | 2009 | 1011 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2008 | 517 | 0.010 |
Why?
|
| Aldehydes | 1 | 2005 | 21 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 2005 | 88 | 0.010 |
Why?
|
| Tyrosine | 1 | 2005 | 132 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2005 | 85 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2012 | 1423 | 0.010 |
Why?
|
| Bradykinin B2 Receptor Antagonists | 1 | 2005 | 1 | 0.010 |
Why?
|
| Bradykinin | 1 | 2005 | 46 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 930 | 0.010 |
Why?
|
| Systole | 1 | 2005 | 116 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 1829 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2005 | 531 | 0.010 |
Why?
|
| Heart Rate | 1 | 2005 | 519 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 2551 | 0.010 |
Why?
|
| Survival Rate | 1 | 2005 | 1986 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2009 | 10286 | 0.010 |
Why?
|